BioNTech SE

Yahoo Finance • 15 days ago

FDA Presses Clinical Hold Button For BioNTech's Partner Late-Stage Trial Of Investigational Lung Cancer Treatment

FDA Presses Clinical Hold Button For BioNTech's Partner Late-Stage Trial Of Investigational Lung Cancer Treatment BioNTech SE (NASDAQ:BNTX) has been notified by its partner, OncoC4 Inc., that the FDA has imposed a partial clinical hold on... Full story

Yahoo Finance • 2 months ago

Pfizer. Inc. (PFE): One of the Best Affordable Stocks Under $40 According to Short Sellers

We recently compiled a list of the 10 Best Affordable Stocks Under $40 According to Short Sellers.In this article, we are going to take a look at where Pfizer. Inc. (NYSE:PFE) stands against the other affordable stocks under $40. Several... Full story

Yahoo Finance • 2 months ago

FDA Approves Pfizer & Moderna's Updated COVID-19 Jabs

The FDA, on Aug 22, approved/authorized the updated mRNA-based COVID-19 vaccines of Pfizer PFE/BioNTech BNTX and Moderna MRNA that target the KP.2 strain of the virus. While the agency approved Pfizer/BioNTech’s Comirnaty and Moderna’s Sp... Full story

Yahoo Finance • 3 months ago

Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?

Pfizer(NYSE: PFE) and BioNTech(NASDAQ: BNTX) recently fell behind in their race with Moderna(NASDAQ: MRNA) to develop new combination shots that could be worth billions in annual sales. Top-line results from an experimental vaccination to... Full story

Yahoo Finance • 3 months ago

Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows

Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows Researchers from the Universities of Cambridge, Bristol, and Edinburgh hav... Full story

Yahoo Finance • 3 months ago

BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products

BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products Monday, BioNTech SE (NASDAQ:BNTX) reported deeper losses in the second quarter of 2024, with an EPS loss of... Full story

Yahoo Finance • 5 months ago

Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season

Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season On Friday, Moderna Inc. (NASDAQ:MRNA) announced that it has submitted an FDA application for review of its Spikevax 2024-2025 formula, which targets the SARS-CoV-2 v... Full story

Yahoo Finance • 6 months ago

European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech

European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech Moderna Inc (NASDAQ:MRNA) has reportedly achieved a significant victory at the European Patent Office (EPO) in its ongoing legal battle with... Full story

Yahoo Finance • 6 months ago

Update: Market Chatter: Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech

Update: Market Chatter: Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech... Full story

Yahoo Finance • 8 months ago

BioNTech Earnings Fall Short of Estimates. The Stock Is Down.

BioNTech the German company that partnered with Pfizer to create Covid-19 vaccines, was falling early Wednesday after reporting earnings that missed analysts’ expectations. The median estimate in a FactSet survey was for an earnings per sh... Full story

Yahoo Finance • 8 months ago

30 Biggest Biotechnology Companies in the World

In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the eve... Full story

Yahoo Finance • 8 months ago

BioNTech Announces Planned Retirement of Sean Marett

BioNTech SE Mainz, Germany, March 7, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Sean Marett, Chief Business and Commercial Officer, will retire as planned from the Management Board... Full story

Yahoo Finance • 8 months ago

16 Best Large-Cap Value Stocks To Invest In in 2024

In this piece, we will take a look at the 16 best large cap value stocks to invest in in 2024. If you want to skip our overview of the latest stock market news, then you can skip ahead to 5 Best Large-Cap Value Stocks To Invest In in 2024.... Full story

Yahoo Finance • 9 months ago

Genmab: Growth Is Still a Better Choice

Genmab AS (NASDAQ:GMAB) is one of the largest Danish pharmaceutical companies focused on developing medicines to treat patients with cancer, multiple sclerosis, thyroid eye disease and various autoimmune diseases. Investment thesis Genma... Full story

Yahoo Finance • 9 months ago

Five Upcoming Class Actions for Investors to Know About

These five recently-filed class action suits could be of interest to investors. Read on to learn about investors’ concerns about the alleged activities of the following companies: MBLY, BNTX, DADA, INSP, ON. Class Action Filed Against Mob... Full story

Yahoo Finance • 9 months ago

Jim Cramer is Recommending These 10 Stocks

In this article, we will take a detailed look at the Jim Cramer is Recommending These 10 Stocks. For a quick overview of such stocks, read our article Jim Cramer is Recommending These 5 Stocks. Jim Cramer said in a latest program on CNBC... Full story

Yahoo Finance • 10 months ago

15 Undervalued Defensive Stocks For 2024

In this article, we discuss the 15 undervalued defensive stocks for 2024. To skip the detailed overview of the market and defensive stocks, go directly to the 5 Undervalued Defensive Stocks For 2024. Defensive stocks are shares of compani... Full story

Yahoo Finance • 11 months ago

BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer

BioNTech SE Designation is based on Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced endometrial cancer with encouraging early signs of anti-tumor activity Breakthro... Full story

Yahoo Finance • 11 months ago

Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today?

A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) related to seeking fair compensation for infringement of a portfolio of CureVac's intellectual property rights utili... Full story

Yahoo Finance • 11 months ago

BioNTech aims to start mRNA vaccine output in Rwanda in 2025

NAIROBI, Dec 18 (Reuters) - COVID-19 vaccine maker BioNTech aims to start production at its mRNA vaccine factory site in Rwanda in 2025, company officials said on Monday, the first foreign company mRNA vaccine manufacturing site on the con... Full story